Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.

Kobayakawa T, Takenaka H, Kobayashi T, Nakamura Y

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA28 Sept 2026

PMID42803810DOI10.1007/s00198-026-08241-wPepBankPUB-42803810

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In matched women with osteoporosis, lumbar spine BMD increased with abaloparatide, without a significant difference from romosozumab.
In plain wordsAbaloparatide was linked to increased spine bone density, with no significant difference from romosozumab.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeLumbar spine BMD change
Study
n = 102
Comparator
Romosozumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Both groups demonstrated significant increases in BMD at all skeletal sites at 12 months (all P < 0.001), with no significant between-group differences.
2 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were percentage changes in lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD over 12 months.
Summary · context
This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were i…
Report a problemFND-4280381001
02HumanObservational studyEfficacy outcome
In matched women with osteoporosis, total hip BMD increased with abaloparatide, without a significant difference from romosozumab.
In plain wordsAbaloparatide was linked to increased total hip bone density, with no significant difference from romosozumab.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeTotal hip BMD change
Study
n = 102
Comparator
Romosozumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Both groups demonstrated significant increases in BMD at all skeletal sites at 12 months (all P < 0.001), with no significant between-group differences.
2 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were percentage changes in lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD over 12 months.
Summary · context
This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were i…
Report a problemFND-4280381002
03HumanObservational studyEfficacy outcome
In matched postmenopausal women with osteoporosis, BMD increased at all skeletal sites at 12 months with abaloparatide, without a significant difference from romosozumab.
In plain wordsAbaloparatide was linked to increased bone density at all skeletal sites, with no significant difference from romosozumab.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeBMD change at all skeletal sites at 12 months
Study
n = 102
Comparator
Romosozumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Both groups demonstrated significant increases in BMD at all skeletal sites at 12 months (all P < 0.001), with no significant between-group differences.
2 context sentences(design, population, supporting numbers)
Summary · context
Primary endpoints were percentage changes in lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD over 12 months.
Summary · context
This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were i…
Report a problemFND-4280381003
04HumanObservational studyEfficacy outcome
In matched women with osteoporosis, hip structural parameters improved with abaloparatide, without significant differences from romosozumab.
In plain wordsAbaloparatide was linked to improved hip structure, with no significant difference from romosozumab.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeHip trabecular and cortical structure
Study
n = 102
Comparator
Romosozumab
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Exploratory 3D-Shaper analyses demonstrated improvements in several trabecular and cortical structural parameters over 12 months, with no significant between-group differences in any parameter.
1 context sentence(design, population, supporting numbers)
Summary · context
This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were i…
Report a problemFND-4280381005
05HumanObservational studyEfficacy outcome
In matched women with osteoporosis, achievement of a T-score above -2.5 increased with abaloparatide, without a significant difference from romosozumab.
In plain wordsMore abaloparatide-treated women achieved a T-score above -2.5 over time, with no significant difference from romosozumab.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeAchievement of T-score threshold
Study
n = 102
Comparator
Romosozumab
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
The proportion of patients achieving a T-score > -2.5 increased over time in both groups without significant between-group differences.
1 context sentence(design, population, supporting numbers)
Summary · context
This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were i…
Report a problemFND-4280381004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.